Similar Posts
Diagnosis and Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Extracts from full Mayo Clinic Article Originally published in October 2023. Selected text and images only included below see full article link at end of page
Extract – Figure 2 shows typical PEM presentations
Publication / Authors
Concise review for clinicians Volume 98, Issue 10, p1544-1551, October 2023: Stephanie L. Grach, MD, Jaime Seltzer, MS, Tony Y. Chon, MD, Ravindra Ganesh, MD, MBBS
Extract – Abstract
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic neurologic disease
Read More “Diagnosis and Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome”
often preceded by infection. There has been increased interest in ME/CFS recently
because of its significant overlap with the post-COVID syndrome (long COVID or post-acute
sequelae of COVID), with several studies estimating that half of patients with post-COVID
syndrome fulfill ME/CFS criteria. Our concise review describes a generalist approach to
ME/CFS, including diagnosis, evaluation, and management strategies.
(c) 2023 THE AUTHORS. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) n Mayo Clin Proc. 2023;98(10):1544-1551#Justice4ME Campaign Update No. 3
Quote from Sarah Boothby on Social Media
We have now taken legal advice, thanks to your donations, and instructed our lawyers to proceed with sending a letter before claim to the Department of Health and Social Care (DHSC). This does not mean there will be a claim (an application to the court for Judicial Review of the Final Delivery Plan for ME/cfs) it means there are inconsistencies within the Plan that make it vulnerable to legal challenge.
We doubt this vulnerability is what was intended in the drafting of the Plan. We know people with ME/cfs have had cross party political support for decades. We know hundreds of people contributed their knowledge, lived experience and expertise to developing the Plan, so we hope these snags will be resolved without a court hearing being necessary. People living with ME, and the NHS staff trying their best to deliver safe clinical care without clear, succinct, safe clinical guidance to follow, deserve nothing less.
If the reply from DHSC to our letter is not satisfactory, and the inconsistencies we have identified in the Final Delivery Plan persist, we must apply for Judical Review by 21 October at the latest.
At this stage, we cannot share with you the advice we have been given but we will explain everything the very first chance we get. Sorry if that’s frustrating; it is for us! If the case does come to court the legal arguments will be made public that way but we hope the DHSC will make the changes needed sooner. The changes needed are not huge, they are efficient, and they will not cost the NHS more money than is already being wasted on catastrophic mismanagement of ME.
This is a first step, made possible only by your generosity and the long history of injustice that got us here. We are honoroued by so many of you sharing your time, comments and money with us. We could not have got so far without you. We rely on your feedback on social media to be sure the aims of #Justice4ME reach the widest audience possible.
More updates will follow in the coming weeks, including additional endorsements and images on our homepage. Meanwhile, please keep on sharing our campaign with everyone you know, however unlikely! Since we met the initial fundraising target in our launch week, the campaign to raise the final third for this first phase will continue throughout October.
Thank you, thank you, thank you for helping make #Justice4ME a serious proposition. Let’s have our NHS knowing what to do about ME without doubts, indecision or delays – all over the UK, please.
#JusticeforME
New Abstract on invasive CPET – Promising outcomes
The American Journal of Respiratory and Critical Care Medicine has posted a new abstract authored by David Systrom et al, which evaluated invasive CPET testing. The test includes iCPET results from 438 ME/CFS patients, 73 Long Covid patients, and 43 symptomatic but otherwise normal controls.
The measurement method is illustrated here from their previous 2023 report [TBA]
The full Abstract within the American Journal of Respiratory and Critical Care Medicine can be found here: https://www.atsjournals.org/doi/abs/10.1164/ajrccm.2025.211.Abstracts.A7881
An image extract from the article is shown below, showing correlation of pVO2 between each cohort and outcomes, and remarkably similar results from ME and Long Covid:
